MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

CRISPR Therapeutics AG

Geschlossen

BrancheGesundheitswesen

32.77 -4.07

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

32.17

Max

34.17

Schlüsselkennzahlen

By Trading Economics

Einkommen

49M

-37M

Verkäufe

34M

35M

EPS

-0.44

Gewinnspanne

-106.603

Angestellte

393

EBITDA

46M

-60M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+109.36% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.2B

Vorheriger Eröffnungskurs

36.84

Vorheriger Schlusskurs

32.77

Nachrichtenstimmung

By Acuity

21%

79%

42 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

CRISPR Therapeutics AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Sept. 2024, 16:08 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26. Sept. 2024, 14:20 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

11. Apr. 2024, 14:46 UTC

Akquisitionen, Fusionen, Übernahmen

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

Peer-Vergleich

Kursveränderung

CRISPR Therapeutics AG Prognose

Kursziel

By TipRanks

109.36% Vorteil

12-Monats-Prognose

Durchschnitt 71.58 USD  109.36%

Hoch 120 USD

Tief 32 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CRISPR Therapeutics AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

20 ratings

12

Buy

7

Halten

1

Sell

Technischer Score

By Trading Central

32.96 / 36.93Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

42 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.